uniQure price target lowered to $47 from $58 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on uniQure (QURE) to $47 from $58 and keeps an Overweight rating on the shares following the Q2 earnings report. The main update from the earnings call is that the statistical analysis plan for AMT-130 in Huntington’s disease has been submitted, the analyst tells investors in a research note. Cantor thinks the September data could be a strong catalyst that could help to make the case that this therapy could be approved.